Navigation Links
Computer with brain connections changing quality of life of paralyzed

Fundamental theories regarding consciousness, emotion and quality of life in sufferers of paralysis from Amyotrophic Lateral Sclerosis (ALS, also known as 'Lou Gerhig's disease') are being challenged based on new research on brain-computer interaction. ALS is a progressive disease that destroys neurons affecting movement. The study appears in the latest issue of Psychophysiology. The article reviews the usefulness of currently available brain-computer –interfaces (BCI), which use brain activity to communicate through external devices, such as computers.

The research focuses on a condition called the completely locked-in state (CLIS, a total lack of muscle control). In a CLIS situation, intentional thoughts and imagery can rarely be acted upon physically and, therefore, are rarely followed by a stimulus. The research suggests that as the disease progresses and the probability for an external event to function as a link between response and consequence becomes progressively smaller, it may eventually vanish altogether.

Researchers have found that by implementing a BCI before the CLIS state occurs, a patient can be taught to communicate through an electronic device with great regularity. The continued interaction between thought, response and consequence is believed to slow the destruction of the nervous system.

The findings are also raising a number of new questions about the quality of life amongst paralysis sufferers. Patients surveyed were found to be much healthier mentally than psychiatrically depressed patients without any life-threatening bodily disease. Only 9% of ALS patients showed long episodes of depression and most were during the period following diagnosis and a period of weeks after tracheotomy.

"Most instruments measuring depression and quality of life are invalid for paralyzed people living in protected environments because most of the questions do not apply to the life of a paralyzed person. Special instruments
'"/>

Source:Blackwell Publishing Ltd.


Page: 1 2

Related biology news :

1. Computers to be used to find blueprint for new influenza drug
2. Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance
3. Computers close in on protein structure prediction
4. Computer modeling reveals hidden conversations within cells
5. Computer models aid understanding of antibody-dependent enhancement in spread of dengue fever
6. Computer-chemistry yields new insight into a puzzle of cell division
7. Computers to save unique type of American red squirrel
8. Computer simulation hints at new HIV drug target
9. Computer scientist sorts out confusable drug names
10. Computer-based games enhance mental function in patients with Alzheimers
11. Computer scientists unravel language of surgery
Post Your Comments:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5